Lineage Cell Therapeutics, Inc.
LCTX· NYSE
LCTXLineage Cell Therapeutics, Inc.
Filed Nov 9, 2012 · 10-Q · 40 days after period end · 0001140361-12-046522
| Metric | Q3 2012 | Q3 2011 | Q3 2010 |
|---|---|---|---|
| Revenue | $1.00M | $1.16M | $815.28K |
| Net Income | -$4.96M | -$3.74M | -$4.67M |
| EPS Diluted | -$0.10 | -$0.08 | -$0.11 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
ended Sep 30, 2012 · filed Nov 9, 2012 · 40 d after period end
